Pressmeddelanden
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") (FN STO: PILA) hereby invites you to participate in these upcoming Nordic investor events:
PILA PHARMA AB Chairman & CEO increase their holdings
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), (FN STO: PILA), today announces that Chairman of the Board, Dorte X. Gram and CEO Gustav H. Gram have purchased additional...
PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN"
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to view and/or listen to the broadcast from todays episode of "Millionærklubben" (Millionaire's Club) where PILA PHARMA's...
REG
MAR
PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN
PILA PHARMA AB (publ) (FN STO:PILA) today announces the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical tria...
REG
MAR
PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsal...
REG
MAR
PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN
PILA PHARMA AB (publ) (FN STO:PILA) today announces it has chosen to alter the operational plan for its next clinical trial, PP-CT03, a phase 2a safety and tolerability trial in...
Rapporter
Video
Finansiell kalender
Bokslutskommuniké 2024
Bokslutskommuniké
Årsredovisning
Årsredovisning
Halvårsrapport 2025
Delårsrapport
Om PILA PHARMA
Webbplats
pilapharma.com
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs ()
Förändring ()